MedTrace Logo

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

NCT02439008 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-03-13

No results posted yet for this study

Summary

This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the hypofractionated high dose radiation therapy and a rationale for adjuvant immunotherapy.

Conditions

  • Carcinoma, Hepatocellular
  • Colorectal Neoplasms
  • Melanoma
  • Kidney Neoplasms

Interventions

PROCEDURE

Blood samples collection before radiotherapy

Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment. Before radiotherapy: * Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy

PROCEDURE

Blood samples collection during radiotherapy

* Sample T1: within 15 minutes after the administration of the first fraction, * Sample T2: within 15 minutes after the administration of the second fraction, * Sample T3: within 15 minutes after the administration of the third fraction

PROCEDURE

Blood samples collection after radiotherapy

* Sample T4: one week after the end of the radiotherapy, * Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy.

RADIATION

Radiotherapy

Sponsors & Collaborators

  • Institut de Biologie de Lille

    collaborator OTHER

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Xavier Mirabel, MD · Centre Oscar Lambret

  • Nadira Delhem, MD · Institut de Biologie de Lille

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-16
Primary Completion
2018-06-21
Completion
2019-03-18

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02439008 on ClinicalTrials.gov